Εylea (aflibercept) intravitreal injections treatment
Aflibercept is a pharmaceutical substance of the drug Eylea. This substance inhibits the activity of a group of factors, known as vascular endothelial growth factors (VEGF) . In patients with central retinal artery occlusion, the central retinal artery or a branch of it is blocked.This results in increase levels of vascular agents (VEGF factors), causing increased macular edema, which because of the fluid collection causes opacities on our vision.
How Eylea is administered?
In the case of secondary macular edema from central retinal vein or artery occlusion personalized treatment is applied, which is determined by your doctor. The frequency of injections which is indicated is one (1) per month. In any case, your doctor will decide whether a patient should continue or discontinue therapy with intravitreal injections. The determinant factor is the improvement of the condition or not, which is judged by measurements of both visual acuity, but mainly by optical coherence tomography (OCT).